跳转至内容
Merck
  • Serotonin (5-HT) inhibits Factor XIII-A-mediated plasma fibronectin matrix assembly and crosslinking in osteoblast cultures via direct competition with transamidation.

Serotonin (5-HT) inhibits Factor XIII-A-mediated plasma fibronectin matrix assembly and crosslinking in osteoblast cultures via direct competition with transamidation.

Bone (2014-12-03)
Cui Cui, Mari T Kaartinen
摘要

Serotonin (5-HT)--a monoamine with a variety of physiological functions--has recently emerged as a major regulator of bone mass. 5-HT is synthesized in the brain and the gut, and gut-derived 5-HT contributes to circulating 5-HT levels and is a negative modulator of bone mass and quality. 5-HT's negative effects on the skeleton are considered to be mediated via its receptors and transporter in osteoblasts and osteoclasts; however, 5-HT can also incorporate covalently into proteins via a transglutaminase-mediated serotonylation reaction, which in turn can alter protein function. Plasma fibronectin (pFN)--a major component of the bone extracellular matrix that regulates bone matrix quality in vivo--is a major transglutaminase substrate in bone and in osteoblast cultures. We have recently demonstrated that pFN assembly into osteoblast culture matrix requires a Factor XIII-A (FXIII-A) transglutaminase-mediated crosslinking step that regulates both quantity and quality of type I collagen matrix in vitro. In this study, we show that 5-HT interferes with pFN assembly into the extracellular matrix in osteoblast cultures, which in turn has major consequences on matrix assembly and mineralization. 5-HT treatment of MC3T3-E1 osteoblast cultures dramatically decreased both pFN fibrillogenesis as analyzed by immunofluorescence microscopy and pFN levels in DOC-soluble and DOC-insoluble matrix fractions. This was accompanied by an increase in pFN levels in the culture media. Analysis of the media showed covalent incorporation of 5-HT into pFN. Minor co-localization of pFN with 5-HT was also seen in extracellular fibrils. 5-HT also showed co-localization with FXIII-A on the cell surface and inhibited its transamidation activity directly. 5-HT treatment of osteoblast cultures resulted in a discontinuous pFN matrix and impaired type I collagen deposition, decreased alkaline phosphatase and lysyl oxidase activity, and delayed mineralization of the cultures. Addition of excess exogenous pFN to cultures treated with 5-HT resulted in a significant rescue of pFN fibrillogenesis as well as type I collagen deposition and mineralization. In summary, our study presents a novel mechanism on how increased peripheral extracellular 5-HT levels might contribute to the weakening of bone by directly affecting the stabilization of extracellular matrix networks.

材料
货号
品牌
产品描述

Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
盐酸多巴胺 盐酸盐
Sigma-Aldrich
噻唑蓝, 98%
Sigma-Aldrich
噻唑蓝, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥97.5% (HPLC)
Sigma-Aldrich
3-(2-氨乙酸)吲哚 盐酸盐, powder
Sigma-Aldrich
3,3′,5,5′-四甲基联苯胺, ≥99%
Sigma-Aldrich
组胺 二盐酸盐, ≥99% (TLC), powder
Sigma-Aldrich
3,3′,5,5′-四甲基联苯胺, ≥98% (TLC)
Sigma-Aldrich
组胺 二盐酸盐, ≥99.0% (AT)
Sigma-Aldrich
戊胺, 99%
Sigma-Aldrich
3,3′,5,5′-四甲基联苯胺, tablet, 1 mg substrate per tablet
Sigma-Aldrich
3,3′,5,5′-四甲基联苯胺, ≥98.0% (NT)
Supelco
盐酸多巴胺 盐酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
二喹啉甲酸 二钠盐 水合物, ≥98% (HPLC)
Sigma-Aldrich
戊胺, ≥99%, FG
盐酸多巴胺 盐酸盐, European Pharmacopoeia (EP) Reference Standard
组胺 二盐酸盐, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
戊胺,异构体混合物, ≥98%
Supelco
3,3′,5,5′-四甲基联苯胺, standard for GC